Beneficial Effect of Silymarin in Ulcerative Colitis

2 points or more decrease in the Mayo score from baseline

The goal of this clinical trial is to evaluate the possible beneficial effect of silymarin in
 Ulcerative Colitis adult patients receiving mesalamine. This is trial that will be conducted
 on 44 adult patients with newly diagnosed Ulcerative Colitis. Patients will be enrolled after
 obtaining an informed consent from them or their guardians.
 
 Patients will be recruited from Rajhy Hospital Outpatient Clinics and Health Insurance
 Outpatient Clinics at Mabarra Hospital in Assiut, Egypt. The patients will be randomized
 based on hospital admission days into two groups:
 
 - Group Ⅰ (control group): 22 patients will receive mesalamine (4g\day induction & 2g\day
 maintenance) only for 6 months.
 
 - Group Ⅱ (silymarin group): 22 patients will receive mesalamine (4g\day induction &
 2g\day maintenance) and silymarin (140 mg\day) for 6 months.
 
 The primary outcome will be clinical improvement defined as a 2 point or more decrease in the
 Mayo score from baseline. The secondary outcomes will be the change in the level of fecal
 calprotectin, superoxide dismutase and TNF-α.